| 前收盘价格 | 20.01 |
| 收盘价格 | 20.62 |
| 成交量 | 1,197,014 |
| 平均成交量 (3个月) | 1,554,316 |
| 市值 | 2,347,513,856 |
| 价格/销量 (P/S) | 252.07 |
| 股市价格/股市净资产 (P/B) | 3.57 |
| 52周波幅 | |
| 利润日期 | 12 May 2026 |
| 营业利益率 (TTM) | -1,525.50% |
| 稀释每股收益 (EPS TTM) | -3.01 |
| 季度收入增长率 (YOY) | 184.40% |
| 总债务/股东权益 (D/E MRQ) | 1.55% |
| 流动比率 (MRQ) | 10.49 |
| 营业现金流 (OCF TTM) | -152.68 M |
| 杠杆自由现金流 (LFCF TTM) | -117.16 M |
| 资产报酬率 (ROA TTM) | -33.54% |
| 股东权益报酬率 (ROE TTM) | -69.21% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Immunome, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
0.7
| 分析师共识 | 2.0 |
| 内部交易活动 | 4.0 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.70 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 11.48% |
| 机构持股比例 | 83.28% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Enavate Sciences Gp, Llc | 31 Dec 2025 | 4,768,583 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (HC Wainwright & Co., 92.77%) | 购买 |
| 中 | 33.50 (61.45%) | |
| 低 | 30.00 (Stephens & Co., 44.58%) | 购买 |
| 平均值 | 34.25 (65.06%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 22.58 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Craig-Hallum | 04 Mar 2026 | 36.00 (73.49%) | 购买 | 22.52 |
| Stephens & Co. | 04 Mar 2026 | 30.00 (44.58%) | 购买 | 22.52 |
| HC Wainwright & Co. | 12 Feb 2026 | 40.00 (92.77%) | 购买 | 22.44 |
| Wedbush | 15 Jan 2026 | 31.00 (49.40%) | 购买 | 22.85 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BIENAIME JEAN JACQUES | 21.40 | - | 1,000 | 21,400 |
| 累积净数量 | 1,000 | |||
| 累积净值 ($) | 21,400 | |||
| 累积平均购买 ($) | 21.40 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | 董事 | 11 Mar 2026 | 买 (+) | 1,000 | 21.40 | 21,400 |
| 日期 | 类型 | 细节 |
|---|---|---|
| 05 Feb 2026 | 公告 | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Feb 2026 | 公告 | Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 08 Jan 2026 | 公告 | Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Jan 2026 | 公告 | Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合